Developer of medical devices designed to improve home patient monitoring. The company's devices aid in the diagnostic evaluation as well as monitoring of therapeutic interventions for multiple medical conditions including trauma, dehydration, and sepsis, enabling physicians to simplify home and critical care, prevent unnecessary acute visits, and improve emergency or critical care.
PneumoNIX Medical is developing gel-based technologies to prevent complications associated with percutaneous procedures such as soft tissue biopsies.
Protabit engineers proteins for industrial, agricultural, and healthcare applications. Its platform technology is being developed via a strategic partnership with the Monsanto Company and the California Institute of Technology. Protabit’s protein engineering approach combines computational modeling with high-throughput screening and directed evolution to expand the diversity of protein sequences that can be explored to produce novel proteins.
BioSuperior is a preclinical stage biotherapeutics company developing cost-effective, non-invasive, and easily accessible technologies to cure lung disease and repair damaged lung tissue. They have bio-engineered a novel synthetic pulmonary surfactant prototype, BioSurf, an essential biomaterial required for breathing and having direct therapeutic effects that will be used to deliver potent drugs that restore normal lung function.
Oculogenex is a biopharmaceutical company based in La Habra, California, established in 2020. The company specializes in developing gene therapies specifically aimed at treating retinal disorders. Its innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced damage, which is a contributing factor to macular degeneration. By focusing on these therapies, Oculogenex aims to enhance the detection and treatment of various retinal disorders, ultimately supporting researchers in advancing novel drug solutions in this critical area of healthcare.
NovoClade is a synthetic biology company focused on developing environmentally friendly solutions for insect control and invasive species eradication. The company utilizes gene-editing technology to create sterile mosquito populations, aiming to mitigate the spread of diseases carried by these insects. By offering chemical-free pest control alternatives, NovoClade provides clients with innovative formulas that effectively reduce disease transmission without harming the environment. Through their advancements in genetic bio-control, NovoClade addresses critical public health challenges while promoting sustainable practices in pest management.
iTherapy offers multi-sensory, universal technology to students with autism and other special needs. The company's technology is used to create educational equipment that improves communication skills by combining science, technology, and play, allowing for better teaching methods for those with learning disabilities. iTherapy was founded by Matthew Guggemos and Lois Jean Brady.
Relavo, LLC is a medical device company founded in 2018 and based in Baltimore, Maryland. The company focuses on developing solutions to prevent infection related to peritoneal dialysis, specifically through its product, The PeritoneX. This device disinfects contamination points prior to the initiation of dialysis treatment, thereby helping patients with kidney failure to lower their risk of developing peritonitis. By offering an affordable means to enhance safety during peritoneal dialysis, Relavo aims to improve patient outcomes in this critical area of healthcare.
Uniphage is a biotech company that eliminates bacterial infections by combining the power of bacteriophages with artificial intelligence. Their first target disease is citrus greening, an incurable and debilitating disease that costs the United States more than $2 billion each year. Uniphage created the first commercially effective models for computationally predicting safe bacterial viruses against target bacterial infections, as well as discovered a variety of targets. This enables them to deliver new antimicrobial, safe, and precise products to market much more quickly.
Iaso Therapeutics develops vaccines to improve human health and cure diseases. The company was founded in 2018 and is based in East Lansing, Michigan.
Acrigen Biosciences focuses on enhancing the safety and efficacy of gene editing technologies, particularly those based on the CRISPR-Cas system. Founded in 2019 and headquartered in Berkeley, California, the company develops innovative solutions that aim to produce effective in vivo drug therapies to combat various diseases. Acrigen's proprietary technologies include Acro proteins that regulate the CRISPR-Cas gene editing process and an advanced bioinformatics discovery software platform that identifies suitable CRISPR systems for human therapeutic applications. Through these advancements, Acrigen Biosciences seeks to improve the precision, efficacy, and safety of genetic therapies, ultimately contributing to the potential prevention and cure of debilitating diseases.
FuturesTHRIVE develops an AI platform to identify and track pediatric mental health easily. FuturesTHRIVE's platform uses a combination of artificial intelligence, sentiment analysis, and machine learning to provide a mental health baseline that can be used by doctors and families to better understand a child's mental health qualities, thereby helping to identify mental health conditions in children easily and early.
Intelligent Medicine provides software and simulation services in medical, artificial intelligence, and virtual reality simulators. Their solution provides architects and facility stakeholders the ability to test and optimize building designs and protocols, thereby reducing infectious spread probability and user congestion.
Auctus Biologics is a pre-clinical biotechnology company focused on developing antibody mimetics for therapeutic and diagnostic uses. By engineering a ribose-binding protein, the company aims to create a scaffold that binds clinical targets with an affinity comparable to monoclonal antibodies while addressing the limitations associated with traditional antibodies. These limitations include instability and the need for costly cold-chain logistics, which can hinder their effectiveness in extreme environments such as the gastrointestinal tract. Auctus Biologics' innovative approach allows for treatments that are not only more resilient, capable of withstanding conditions like repeated boiling cycles, but also more accessible and cost-effective for patients. This advancement may significantly enhance the delivery of advanced medical therapies.
Oncurie specializes in developing targeted radionuclide therapies aimed at treating metastatic cancer. The company employs innovative molecular radionuclide technology to deliver radionuclides selectively to metastatic tissues, enhancing treatment efficacy. By focusing on this advanced therapeutic approach, Oncurie seeks to provide healthcare providers with the tools needed to effectively cure patients suffering from breast cancer and other metastatic conditions.
DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.
MBF Therapeutics, Inc. is a clinical-stage veterinary oncology company dedicated to developing innovative therapies for dogs and cats with cancer. The company's portfolio includes targeted immunotherapies and small molecule drugs designed to disrupt tumor cell metabolism while sparing normal healthy cells. Notable products in development include MBFT-101, a combination therapy for sarcomas and lymphoma that merges a polyamine transport inhibitor with a potent enzyme inhibitor, and MBFT-102, an immunotherapy based on the tumor suppressor mda-7/IL24, which has shown promise in human cancers. Additionally, MBF Therapeutics is exploring gene-based immunotherapeutic vaccines, aiming to revolutionize cancer treatment and infectious disease prevention in companion animals and livestock. The company collaborates with the Lankenau Institute for Medical Research and is headquartered in Ambler, Pennsylvania.
Quadralynx specializes in the development of wearable biometric devices tailored for adults experiencing motor speech disorders, particularly those who face challenges with volume control due to Parkinson's disease and similar neurological conditions. The company's innovative device employs biofeedback technology to alert users through vibrations when their voice reaches a pathological state. By focusing on speech and voice improvement, Quadralynx aims to enhance the quality of life for individuals affected by these disorders.
Akttyva Therapeutics focuses on developing targeted therapeutics aimed at addressing cell barrier dysfunction, particularly in vascular barrier disorders. The company leverages its understanding of biological pathways, along with artificial intelligence and machine learning, to design innovative treatments. By concentrating on the structural aspects of cell barriers, Akttyva Therapeutics aims to provide solutions that enable healthcare professionals to effectively manage various medical conditions related to cell barrier dysfunction.
Synvivia makes ON-OFF switches for genetically engineered organisms. These protein switches are controlled by small molecules. By installing these switches into an organism, Synvivia creates engineered organisms that can be controlled with small molecules.
OPOS operates a patient monitoring and opioid prescriber compliance platform designed to assist primary care and pain specialists across various practice settings. The company focuses on ensuring that opioid prescribers adhere to guidelines set by the Centers for Disease Control and Prevention, state authorities, and medical boards. By providing documented evidence of compliance, along with clinical decision support, OPOS enables healthcare providers to enhance patient outcomes and assess individual and collective risks associated with patients, prescribers, and practices. Their services not only promote regulatory compliance but also aim to reduce prescribing risks and administrative overhead, thus generating revenue through improved operational efficiency in opioid treatment.
BioSapien is a biotech startup that focuses on developing a 3D printed drug delivery platform to provide FDA approved drugs. The startup's device allows chemotherapy to be delivered intravenously through a controlled drug release and enables physicians to reduce harmful side-effects and dramatically reduce costs. BioSapien was established in 2018 and is based in New York.
Medecipher is a highly innovative early stage company providing innovative solutions to help hospitals improve their operations.
Felix Biotechnology, founded in 2019 and based in San Francisco, California, is focused on developing biotherapeutics aimed at addressing microbial challenges in human health, particularly antibiotic-resistant strains of bacteria and fungi. The company aims to accelerate the deployment of innovative treatments for infectious diseases, enabling healthcare professionals to manage these urgent health threats effectively. Through its targeted approach, Felix Biotechnology seeks to provide precise and effective solutions to combat the growing issue of antibiotic resistance.
Immergo is a company that specializes in a virtual reality telehealth platform aimed at enhancing remote physical rehabilitation. Founded in 2020 and based in Santa Cruz, California, Immergo's platform offers an all-in-one solution for therapists, providing improved accessibility, affordability, and accuracy in delivering rehabilitation services. By utilizing a headset, the platform eliminates the physical overhead costs typically associated with therapy clinics, allowing therapists to effectively double patient throughput. It also incorporates biomechanical analysis and automates the tracking of patient success metrics, enabling therapists to provide comprehensive care remotely while overcoming the limitations of traditional telehealth.
xMD Diagnostics operates in the healthcare industry focusing on biotechnology business. The company was formerly known as Bay Resources Development Group. The company is headquartered in Annapolis, Maryland. xMD Diagnostics uses high-throughput microdissection technology for the diagnosis of cancer.
Developer of gastrointestinal therapeutic device designed for the alleviation of postoperative ileus and the restoration of gastrointestinal motility. The company's device aims to revolutionize medical science by using bioelectronic medicine for the treatment of diseases and injuries incurable pharmaceutically and is capable of developing miniaturized implantable device, while retaining sophisticated functionality with various electrode shape and number, enabling clinicians to treat diseases and injuries through neuromodulation.
TRGel develops glucose-based biopolymers that can be used instead of calcium alginate for encapsulation. The company was founded in 2010 and is based in Irvine, California.
TheraCea Pharma is a biotechnology company that develops precision medicine to help people with neurological disorders. TheraCea Pharma, a University of Arizona spin-off based in Tucson, developed and licensed radiochemistry technology that allows for high-efficiency and rapid fluorine-18 radiolabeling of biomolecules for clinical and research applications.
Kodikaz Therapeutic Solutions is focused on advancing cancer treatment by developing targeted therapies aimed at eradicating cancers while minimizing side effects. The company utilizes its innovative Zip-Code™ Technology platform, a first-in-class delivery system that facilitates cell-specific genomic transfer for both RNA and DNA applications. Rooted in discoveries from human cancers, this platform addresses the limitations associated with traditional viral delivery methods, providing a more effective and safer alternative. Kodikaz's research generates valuable in-vitro and in-vivo data across various oncological applications, including pancreatic, myeloma, and colorectal cancers, supporting the development of curative gene transfer technologies.
Developer of industrial enzymes intended to provide high value enzymes and chemical entities to businesses. The company develops combination of disparate disciplines to overcome problems that are not amenable to throughput screening methodologies in order to discover new, high value enzymes and chemical entities, enabling organizations to produce and market chemical products and processes through contract or in partnership .
Developer of neurodiagnostic technologies intended to commercialize blood testing products. The company provides critical data that can be useful in diagnosis, monitoring and assessing therapeutic responses that help to make discoveries for brain health and diseases, enabling pharmaceutical companies and researchers to drug discovery and conduct studies in brain disease.
KovaDx focuses on improving healthcare access for individuals suffering from Sickle Cell Disease and other hemolytic anemias through an innovative point-of-care solution. The company has developed a health monitoring tool that utilizes Quantitative Phase Imaging and deep learning technology to provide affordable and easy-to-use diagnostics. This system is designed to bridge gaps in care for blood diseases, enabling better management of blood health. By offering a diagnostic and monitoring device, KovaDx aims to enhance the understanding of treatment impacts and improve patient outcomes. Ultimately, the company seeks to support individuals with Sickle Cell Disease in enhancing their overall prognosis and quality of life.
Nano PharmaSolutions improves the bioavailability of insoluble drugs using innovative, revolutionary nanoformulation. Nano PharmaSolutions offers a phase-transition technology platform that can reliably enhance the solubility of BCS 2 and BCS 4 APIs without the use of excipients (e.g. large volumes of volatile solvents) used in such processes as spray dry dispersion, hot-melt extrusion, and emulsification. Their patented technology platform deposits vaporized API onto the surface of a carrier molecule which is further processable into the full spectrum of existing dosage forms.
Verboso develops a speech therapy platform designed to make speech therapy fun, engaging, and data driven using video games powered by AI. The company's platform leverages AI to provide a non-binary grade of speech therapy exercises in real-time allowing the user to control a video game while tracking compliance and improvement data, enabling parents to engage their children in speech therapy sessions while having fun at the same time.
Developer of virus-resistant live bacterial products designed to modulate the human microbiome. The company targets the viral components of the gut microbiome to treat disease and focus on healthy gut bacteria and their predatory phages to engineer resistant strains, and also develops a new class of live biotherapeutics, enabling medical science professionals to specifically target phages or viruses with a specific affinity for inducing lysis.
HC Simulation, founded in 2011 and headquartered in Canton, Mississippi, focuses on developing advanced products that utilize the HumMod engine to simulate human physiology. The company's offerings allow users to explore physiological interactions that are often difficult to observe through traditional methods. By providing high-quality simulations, HC Simulation aids in the ideation, development, and prediction of innovative medical devices and pharmaceuticals, enhancing the understanding of complex biological systems.
Hermes Life Sciences develops solutions to improve the accuracy and accessibility of blood testing at the point of care. The company was founded by Sasank Vemulapati.
Theromics Inc. develops cell therapies. It offers HeatSYNC Gel, a thermal accelerant (TA) that augments MW and RF energy by increasing local tissue electrical conductivity in a reproducible and effective manner. The company’s TA absorbs microwave energy effectively preventing heat loss caused by blood flow in large vessels adjacent to ablation zone; optimizes the shape of the ablation zone into a circle making the ablation volume predictable; and produces a larger ablation area making it easier to target the tumor center and with 3-D modeling optimizes antenna guidance into tumor mass. Theromics Inc. was founded in 2016 and is based in West Bridgewater, Massachusetts.
Sequitur Health develops a blood biomarker monitoring device with the aim of saving, extending, and improving people's lives. The company was founded in 2019 and is headquartered in Scottsdale, Arizona.
Inherent Targeting develops fluorescent contrast agents that target nerves to improve surgical outcomes. The company was founded in 2019 and is headquartered in Portland, Oregon.
SingletO2 Therapeutics is a biotechnology company founded in 2015 and based in New Providence, New Jersey. The company focuses on developing innovative treatments for periodontal disease by utilizing the unique properties of singlet oxygen. This advanced approach capitalizes on the bacteria-killing capabilities of singlet oxygen, enabling clinicians to effectively treat advanced stages of periodontal disease without the need for surgical intervention. Through its research and development efforts, SingletO2 Therapeutics aims to improve patient outcomes and transform the management of periodontal health.
MedChem Partners is a medicinal chemistry CRO that specializes in developing small molecule therapeutics. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Drive Therapeutics is a biotechnology company focused on enhancing treatments for retinal diseases. The company is developing therapeutics specifically aimed at addressing wet age-related macular degeneration and diabetic retinopathy, including diabetic macular edema. Through its innovative approach, Drive Therapeutics aims to provide more effective solutions for patients suffering from these serious eye conditions.
Paramita Therapeutics is a San Diego-based biotech company established in 2018 that specializes in developing innovative therapeutics for cancer and infectious diseases. The company employs a patented multi-functional chemical platform to facilitate the rapid transition of new therapies from the laboratory to clinical settings. By focusing on multivalent drug conjugates derived from recognized and approved molecules with established safety and toxicology profiles, Paramita Therapeutics aims to enhance patient access to effective cancer treatments and dual-function therapeutic and vaccine products.
Cordance Medical is a medical device company focused on developing innovative therapies for central nervous system (CNS) pathologies, including primary and metastatic cancers, Alzheimer's disease, and Parkinson's disease. The company has created a non-invasive ultrasound system that precisely opens the blood-brain barrier, allowing for targeted delivery of systemically administered drugs to specific brain regions. This low-power ultrasound technology aims to enhance diagnostic and therapeutic options for patients, providing a safe and effective means to address complex neurological conditions.
Developer of recombinant protein-based materials designed to mimic those naturally found in this environment. The company's products have core protein biometrics composed of a simple modular design, translated into a system that forms fractal-like porous networks with material properties after injection and exposure to body heat, enabling medical researchers to get the required bio-compatible materials used in tissue engineering and regenerative medicine.
Avior Bio is a clinical-stage pharmaceutical company focused on developing innovative treatments for neurological conditions and pruritus in patients with liver disease. The company utilizes its proprietary Speedit™ Transmucosal Film Technology, which allows for effective drug delivery by bypassing first-pass metabolism and minimizing the production of glucuronide metabolites excreted by the kidneys. This technology aims to provide significant relief from various symptoms, including insomnia, anxiety, depression, and excoriation. With a strong management team, an experienced advisory board, and dedicated scientists, Avior Bio is well-positioned to deliver safe and effective therapeutic solutions to improve patient outcomes.
Tacit Therapeutics is a biotechnology company focused on developing RNA-targeted treatments to address genetic diseases. Founded in 2021 and based in South San Francisco, California, the company utilizes pre-existing components of human cells to create innovative, non-immunogenic methods for repairing mutated genes. By offering a broadly applicable approach to gene modification, Tacit Therapeutics aims to provide effective solutions for genetic conditions that were previously deemed untreatable, thereby enabling advancements in the treatment of devastating diseases.
Ethos Medical Inc is a medical device manufacturer specializing in ultrasound-based needle guidance systems for procedures such as spinal taps and epidurals. Founded in 2018 and headquartered in Duluth, Georgia, the company has developed the Iris, a handheld device that assists practitioners in accurately navigating needles into the spine. This system interfaces with existing ultrasound machines, providing real-time tracking and guidance, which enhances the precision of needle-based procedures. Ethos Medical aims to improve the efficiency and accuracy of healthcare delivery while maintaining cost-effectiveness.
SpheroFill is a drug delivery platform that specializes in the development of injectable tissue fillers, particularly for treating age-related atrophy in the larynx. The company utilizes a unique combination of solid, hollow, and porous-wall hollow glass microspheres mixed with biocompatible and bioactive matrices. This innovative approach enhances the delivery of active pharmaceutical ingredients (APIs) in various forms, including solids, liquids, and gases. By improving compliance through reduced dosing frequency and enabling previously impossible oral formulations, SpheroFill is positioned as a leader in advancing drug delivery technology, offering healthcare professionals enhanced devices for more effective treatments.
NeuroLogic Solutions, established in 2016 and based in Baltimore, Maryland, develops advanced EEG analytic software aimed at enhancing the diagnosis and treatment of epilepsy. The company’s platform analyzes electroencephalography data to identify regions of the brain affected by seizures, which assists clinicians in diagnosing epilepsy more accurately and guiding surgical interventions. By providing insights that can lead to seizure freedom, NeuroLogic Solutions seeks to improve patient outcomes and contribute to the overall effectiveness of epilepsy care.
Current Surgical is a surgical device company that develops precise tools for the treatment of solid tumors. The company was founded in 2020 and has its headquarters in Washington, DC.
Winter Innovations is focused on developing medical devices aimed at enhancing patient outcomes following orthopedic injuries. The company is working on EasyWhip, a patent-pending suturing needle specifically designed for orthopedic ligament and tendon reconstruction surgeries. This innovative device simplifies and standardizes the whip stitching technique, providing benefits such as ease of use, speed, stability, and versatility. By improving the speed and consistency of orthopedic reconstruction procedures, Winter Innovations aims to support surgeons in delivering more effective treatments for their patients.
NellOne Therapeutics, Inc. is a regenerative medicine company based in Oak Ridge, Tennessee, focused on developing and commercializing protein therapeutics aimed at restoring cardiac muscle mass and function in patients recovering from myocardial infarction and congestive cardiac failure. Established in 2007 and spun out from the U.S. Department of Energy's Oak Ridge National Laboratory, NellOne's foundation is rooted in research conducted by Dr. Cymbeline Culiat, who identified the therapeutic potential of the Nell1 gene pathway in tissue regeneration. The company’s primary goal is to translate scientific discoveries into clinical applications that improve recovery outcomes for individuals affected by heart conditions.
Precision Theranostics is a biotechnology company based in Baltimore, Maryland, founded in 2019. The company focuses on developing prognosis-based intervention strategies aimed at the early detection and treatment of fatal diseases. Its innovative platform is designed to estimate disease progression, particularly for respiratory diseases and age-related disorders. By creating novel diagnostics, therapeutics, and prognosis-based therapies, Precision Theranostics enables healthcare providers to deliver timely diagnoses and interventions, ultimately improving survival rates and preventing the progression of chronic and fatal conditions.
CellDrop Biosciences, established in 2017 and based in Laramie, Wyoming, specializes in hydrogel-based technology for point-of-care diagnostics and targeted biomaterial delivery. The company focuses on developing hydrogel platforms that enable precise control over chemical and biological systems. Its innovations aim to facilitate the healing of equine musculoskeletal injuries efficiently, while also minimizing the risk of re-injury. By providing effective diagnostic and treatment solutions, CellDrop Biosciences addresses critical needs within the veterinary medical community.
Oculogenex is a biopharmaceutical company based in La Habra, California, established in 2020. The company specializes in developing gene therapies specifically aimed at treating retinal disorders. Its innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced damage, which is a contributing factor to macular degeneration. By focusing on these therapies, Oculogenex aims to enhance the detection and treatment of various retinal disorders, ultimately supporting researchers in advancing novel drug solutions in this critical area of healthcare.
Epivara, founded in 2016 and based in Champaign, Illinois, is developing a single-injection alternative to traditional spaying and neutering surgeries. This innovative approach aims to provide a safer and less invasive method for sterilizing pets, eliminating the pain and risks associated with conventional surgical procedures. By utilizing a small capsule, Epivara's solution offers the benefits of neutering, such as preventing overpopulation and reducing reproduction-related diseases, while also sparing pet owners from the costs and lengthy recovery times of surgery. The company's mission centers on enhancing the well-being of animals and their owners through compassionate care and cutting-edge scientific advancements.
Enable Therapeutics
Grant in 2021
Enable Therapeutics is a biotechnology company developing a patented drug delivery platform. The company was founded in 2020 and is headquartered in Hopedale, Massachusetts.
Impact Proteomics, LLC specializes in protein sample preparation, offering a range of kits and reagents designed to produce contaminant-free samples. Founded in 2017 and based in Pittsburgh, Pennsylvania, the company provides various products, including Universal Protein Extraction and Clean Kits for peptides, whole proteins, and immunoprecipitation, as well as Promtag Reversible Protein Tagging Agents and related accessories. By supplying tools for efficient protein handling, Impact Proteomics aims to enhance drug and biomarker discovery processes, allowing researchers to accelerate the development of therapeutics and diagnostics. The company's offerings are available for purchase online, reflecting its commitment to supporting the scientific community in advancing medical research.
Nabla is an autoreverse platform that enables the rapid discovery of previously unattainable protein variants with supernatural qualities.Nabla Bio makes new medicines and improve nutrition by engineering novel proteins.
NeyroblastGX is a biotechnology company established in 2020 and based in Murrieta, California, focused on developing theranostic products aimed at treating neurodegenerative and infectious diseases. The company’s product offerings include a blood-based biomarker diagnostic for Alzheimer's, genetically engineered dendritic cells designed to eliminate custom-made human organoids for drug screening, cellular toxicity assessment, and disease pathology. Additionally, NeyroblastGX develops an oral supplement intended to enhance protective immunity, providing patients with a comprehensive portfolio of diagnostics, drugs, and therapies to combat life-threatening conditions.
Cartilage is a biotechnology company founded in 2019 and based in Irvine, California. It specializes in developing tissue-engineered regeneration products aimed at healing both focal and large cartilage defects. The company's innovative platform utilizes a viscous injectable to address the early signs of cartilage injury, promoting enhanced integration of the cartilage. This approach allows for effective treatment of various cartilage defects, offering patients improved healing outcomes compared to existing therapies.
BondTrue LLC is a medical device company focused on enhancing surgical accuracy through automation. The company's patented device automates the processes of surgical incisions and closures, allowing for rapid approximation and repair of surgical wounds. This innovation enables surgeons to execute clean, consistent incisions and achieve precise suturing. Recently, BondTrue received a Phase II Maryland Industrial Partnerships (MIPS) award from the Maryland Technology Enterprise Institute, which provides funding for research and development in collaboration with universities. The $100,000 grant will support the continued development of the device, following successful completion of Phase I. BondTrue plans to refine its prototype designs, which will undergo further research and testing to advance the commercialization of this medical technology.
Nanoxort, founded in 2018 and based in Auburn, Alabama, specializes in developing diffusive magnetic fractionation (DMF) technology that allows precise control over the properties of magnetic nanomaterials. This innovative technology is particularly significant in the healthcare sector, as it enhances contrast agent injections for patients undergoing MRI scans. By improving image resolution, Nanoxort's technology reduces the toxic effects associated with traditional MRI contrast agents, particularly gadolinium, which poses risks for individuals with compromised kidney function. Consequently, Nanoxort's advancements contribute to safer imaging practices, minimizing gadolinium exposure for patients who require frequent MRI procedures.
CytoRecovery, Inc. is a company specializing in the development of microfluidic technology aimed at recovering and analyzing subpopulations of cancer cells from tumor biopsies and other biological samples. Founded in 2017 and headquartered in Blacksburg, Virginia, CytoRecovery's innovative technology allows cell biologists and life science researchers to efficiently select and retrieve rare, homogeneous, and viable cell subpopulations from tissues and blood. The technology facilitates individual trapping and release of these rare cells, enabling more effective downstream analysis and enhancing research capabilities in cancer biology and related fields.
Active Therapy Systems is a company based in Nicholasville, Kentucky, founded in 2017. It specializes in developing an interactive exercise platform designed to provide in-home therapies for individuals living with Parkinson's disease. The platform aims to enhance the management of Parkinson's through personalized therapies and remote patient monitoring, allowing users to engage in activities that may help alleviate their symptoms. By focusing on the specific needs of those affected by Parkinson's, Active Therapy Systems seeks to improve their quality of life and promote greater independence in daily activities.
FibrosIX is a biotechnology company develops drugs to prevent lung fibrosis in cancer patients. The company was founded in 2016 and is headquartered in East Lansing, Michigan.
Gradient Medical develops novel interventional oncology services to bring ACE therapy to the clinic. The company was founded in 2020 and is headquartered in Raleigh, North Carolina.
AthemBio develops game-changing technologies and turns them into solutions to major bioprocessing challenges encountered during biologics manufacturing.
Grit Bio develops cancer therapeutics with the goal of providing a safer approach to treating pharyngeal squamous cell carcinoma. The company was founded in 2017 and is headquartered in New York, NY.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.
Developer of RNA therapies designed to inoculate trees, vines, and bushes against diseases, eliminating the need for genetic modification. The company's RNA therapy includes introducing a virus like RNA bacterial inside the tree veins to destroy viral and fungal pathogens, enabling food growers to ensure abundant and diverse food supplies while protecting natural resources.
iReprogram is a cell regeneration laboratory based in Ann Arbor, Michigan, established in 2017. The company focuses on advancing personalized medicine through innovative cell reprogramming technology. By utilizing a high-fidelity computational tool, iReprogram generates transcription factor recipes aimed at facilitating cellular trans-differentiation. This approach enhances treatment options for cancer patients, contributing to improved therapeutic outcomes. Through its research and development efforts, iReprogram seeks to accelerate the delivery of next-generation medical solutions tailored to individual patient needs.
Eradivir is a biotech company established in 2020 and based in West Lafayette, Indiana. The company focuses on developing a novel bispecific immunotherapy platform aimed at combating the virus responsible for COVID-19. Eradivir's approach involves creating non-immunological targeting agents that possess high specificity and avidity for a unique domain of the spike protein found on various coronaviruses. This innovation enables the effective elimination of both free viruses and virus-infected cells, even during advanced stages of infection, thereby empowering patients' immune systems to address viral challenges more efficiently.
Souvie Biodelivery develops drug delivery services with the goal of marketing novel drug delivery platforms to drug delivery niche markets. The company was founded in 2018 and is headquartered in Tucson, Arizona.
Progenitor MDX provides a comprehensive and customizable solution to manage COVID-19 infections from start to finish. We not only deliver testing results, but also help you develop actionable plans for infection management, providing reassurance to your communities.
Akanocure's mission is to synthesize and develop biotargeted anti-cancer chemotherapeutic drugs derived from natural sources. Akanocure's pipeline will consist of analogs of fully validated, highly potent anti-cancer natural products that can only be produced on a large scale through Akanocure's proprietary CCC synthesis platform. The company has competitive edges on two fronts: the synthesis platform that gives Akanocure exclusive access to rare compounds and the potential pipeline of anti-cancer products that are far superior to existing therapies.
BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.
Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. It specializes in developing and commercializing silk biomaterial technologies aimed at improving vaccine delivery and storage. The company has created the MIMIX microneedle platform, which facilitates transdermal delivery of vaccines and therapies, and the MATRIX formulation and drying platform, which enhances the stability of vaccines, therapeutics, and diagnostic products. By utilizing a silk-derived protein, Vaxess enables vaccines to be stored and transported without refrigeration, thereby reducing distribution costs and increasing access to essential healthcare products globally.
Ernest Pharmaceuticals is a biotechnology company based in Hadley, Massachusetts, founded in 2016. The company specializes in developing innovative bacterial therapeutics aimed at treating cancer. Its unique approach involves programming bacteria to deliver intracellular macromolecules directly into tumor tissues. These engineered bacteria are motile, allowing them to actively penetrate and target metastatic diseases and inoperable tumors. Through these advancements, Ernest Pharmaceuticals aims to enhance treatment options for patients facing challenging cancer diagnoses.
Creative BioTherapeutics is a biotechnology company developing therapies for cancer and viruses. The company is changing the way that cancer and viral disease research is conducted. It focuses on the root cause of cancer affecting immune evasion and drug resistance.
Developer of encapsulation technology-based drugs designed to use biologics, peptides, and RNA to treat disease. The company's technology addresses current issues with many biologics and peptide therapeutics, by protecting and delivering agents to their intended targets within the body, enabling patients with sustained delivery of peptide therapeutics using nano-composite microparticles.
Developer of a medical technology designed to offer treatment for heart failure. The company's technology specializes in offering advanced transcatheter heart valve therapies, enabling patients to prevent structural heart failure.
Saphtx develops protein-based therapeutic strategies for a wide range of diseases. The company was founded in 2018 and is headquartered in Newark, New Jersey.
TEGA Therapeutics, Inc. is focused on developing glycoscience-related technologies aimed at treating life-threatening diseases. Founded in 2013 and based in La Jolla, California, the company specializes in enhancing the delivery of enzyme replacement therapies to the brain, particularly for lysosomal storage disorders. By leveraging glycoside-enhanced delivery methods, TEGA addresses significant challenges in reaching the central nervous system, thereby improving treatment outcomes. Additionally, the company produces bio-engineered heparan sulfate and heparin, which play crucial roles in various physiological processes. TEGA's mission is to improve the quality of life for patients by providing innovative solutions for unmet medical needs, utilizing rigorous scientific methods to advance the therapeutic potential of glycans in medicine.
Seven Biosciences provides drug discovery platforms for G-protein coupled receptors. The company, based in Davis, California, was founded by Grace Mizuno and Lin Tian.
Ionica Sciences™ is utilizing a new technology platform to meet urgent needs in clinical diagnostics.The ability to rapidly and accurately identify the presence of diseases would provide clinicians with the ability to reduce suffering of their patients, the use of antibiotics, and healthcare costs that result from mis- or missed diagnoses.
Relavo, LLC is a medical device company founded in 2018 and based in Baltimore, Maryland. The company focuses on developing solutions to prevent infection related to peritoneal dialysis, specifically through its product, The PeritoneX. This device disinfects contamination points prior to the initiation of dialysis treatment, thereby helping patients with kidney failure to lower their risk of developing peritonitis. By offering an affordable means to enhance safety during peritoneal dialysis, Relavo aims to improve patient outcomes in this critical area of healthcare.
Flotherm develops a thermal compression device that maintains normothermia in a timely manner. The company's headquarters are in Los Angeles, California.
FYR Diagnostics, founded in 2016 and based in Missoula, Montana, focuses on developing biomarker detection technology aimed at addressing chronic diseases in both human healthcare and agriculture. The company aims to tackle significant clinical challenges by commercializing innovative technologies that enhance the prediction, diagnosis, and management of diseases. This approach targets disorders that currently suffer from inadequate treatment and diagnostic options, thereby offering potential solutions for healthcare professionals and agricultural sectors facing substantial unmet needs.
Omnicyte is a biotechnology company focused on developing targeted treatments for cancer therapy. It utilizes a proprietary Immuno-Oncology Platform Technology to create recombinant targeted immunomodulators aimed at addressing unmet medical needs in oncology. The company is actively working on treatments for various cancer indications, including ovarian cancer and small cell lung cancer. By advancing its innovative platform, Omnicyte aims to enhance patient outcomes and improve quality of life for individuals affected by these challenging diseases.
Solving gout using engineered probiotics
Dynamic Entropy Technology manufactures medical devices with the purpose of improving new technologies in the field of health sciences. The company was founded in 2018 and is headquartered in Pasco, Washington.
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision’s CLIA-certified, central laboratory in Pittsburgh. Plexision currently offers cell-based testing for personalized assessment of rejection risk after solid organ transplantation The Pleximmune blood test is the first such test offered for children with liver or intestine transplantation.
Altrix Medical, founded in 2013 and based in Centreville, Virginia, is a medical company focused on developing online applications and medical equipment aimed at enhancing health outcomes. The company specializes in a portable smart automated external defibrillator designed to address cardiac arrest. This device is linked to an application that alerts first responders and provides the patient's location, facilitating prompt on-site diagnosis and treatment of sudden cardiac events. Through its innovative solutions, Altrix Medical seeks to improve the effectiveness of emergency medical responses and ultimately enhance patient care.
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.
Thermaquil, Inc. develops and sells medical devices to control pain and other conditions caused by overactive nerves. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.
Jupiter Therapeutics is a biotechnology company specializing in the development of cell-membrane-based therapeutics. The company employs a synthetic biology approach to rapidly design and synthesize a diverse pipeline of therapeutic assets targeting cancer, autoimmune diseases, drug delivery, and gene therapy. By utilizing advanced cell engineering techniques, Jupiter Therapeutics creates customized vesicles that enhance immuno-oncology applications and gene therapy strategies. This innovative approach allows medical researchers to leverage insights gained from cell-membrane studies to improve treatments involving CAR T-cells and bi-specific antibodies.